Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
106 participants
OBSERVATIONAL
2021-05-01
2023-10-16
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
How does gut microbiota dysbiosis impact functional recovery in subacute SCI patients, in a way that future targeted probiotic interventions may improve SCI outcomes?
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Examining the Distal Gut Microbiome After Spinal Cord Injury
NCT03319225
Gastrointestinal and Urinary Tract Microbiome After SCI
NCT02903472
Abdominal Functional Electrical Stimulation to Improve Bowel Function in Spinal Cord Injury
NCT06345781
Enhancing Recovery in Non-Traumatic Spinal Cord Injury
NCT03320759
An Online Rehabilitation Programme for People with SCI
NCT06583538
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Spinal cord injury (SCI) is a devastating condition with no effective cure. Gut dysbiosis and chronic immune dysfunction are common complications that may hinder recovery. This study aims to investigate the role of gut microbiota and related immune biomarkers and metabolites in the functional recovery of SCI patients during the subacute phase. This study hypothesizes that alterations in the gut microbiota and associated immune responses are critical factors influencing recovery trajectories in patients during the subacute phase of SCI.
Therefore, we aim to investigate the intricate relationship between gut microbiota composition, immune biomarkers, and functional outcomes in this population, to develop a probiotic-based therapeutic intervention.
Study Objectives:
* To characterize gut microbiota changes in subacute SCI patients;
* To identify microbiota-based biomarkers for prognosis;
* To correlate gut dysbiosis with systemic inflammation and functional recovery.
Exploratory objective:
\- To assess the potential of probiotic-based approaches for therapeutic intervention.
Study Design and Methodology:
This is an observational, longitudinal, prospective cohort study involving 66 patients with subacute SCI (28 patients with A and B classification in ASIA Impairment Scale - AIS and 38 patients with C and D classification in AIS) and 40 able-bodied control participants.
Participant Recruitment and Enrollment:
Participants admitted for hospitalization at Centro de Reabilitação do Norte (CRN)/Unidade Local de Saúde de Gaia e Espinho (ULSGE) were recruited. Inclusion and exclusion criteria were clearly defined to ensure a homogenous study population.
Data Collection:
Clinical data, including neurological assessments, functional outcome measures (e.g., ASIA Impairment Scale, Functional Independence Measure), and demographic information, were collected at three time points:
T1: Admission to the rehabilitation unit (subacute phase). T2: Discharge from the rehabilitation unit. T3: One-year post-injury follow-up. Biological samples, including fecal samples and blood samples, were collected at each time point (T1, T2, and T3).
Laboratory Analyses:
Microbiome Analysis: Fecal samples undergone 16S rRNA gene sequencing to determine gut microbiota composition and diversity.
Immune Biomarker Quantification: Blood samples were analyzed to quantify levels of key inflammatory cytokines, chemokines, and other immune markers.
Metabolite Profiling: Fecal samples, and/or blood samples will be analyzed using metabolomics techniques to identify gut-derived metabolites that may influence recovery.
Statistical Analysis:
Descriptive statistics (means) were calculated for all outcome measures. Data association studies included gut microbiota composition, AIS-based rehabilitation outcomes (percentage improvement), comorbidities (e.g., UTIs), immune biomarkers, and metabolites at T1-T3, with focus on microbiota linked to SCI. Potential confounders (age, gender, injury level, etc.) and biases were accounted for.
Independent group comparisons (e.g., T1 cytokine levels) used t-tests or Mann-Whitney U-tests, while dependent group comparisons (e.g., cytokine changes within AIS groups) used paired t-tests or Wilcoxon tests. ANOVA, multivariate analyses, and generalized linear models (regression, mixed-model repeated measures) assessed inter-group data and associations between gut microbiota changes and functional/immunological outcomes.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Spinal cord injury patients - A or B AIS classification
Spinal cord injury patients admitted for hospitalization at Centro de Reabilitação do Norte, Unidade Local de Saúde de Gaia / Espinho, E.P.E. with A (complete) or B (sensory incomplete) classification in The American Spinal Injury Association (ASIA) Impairment Scale (AIS)
No interventions assigned to this group
Spinal cord injury patients - C or D AIS classification
Spinal cord injury patients admitted for hospitalization at Centro de Reabilitação do Norte, Unidade Local de Saúde de Gaia / Espinho, E.P.E. with C or D (motor incomplete) classification in The American Spinal Injury Association (ASIA) Impairment Scale (AIS)
No interventions assigned to this group
Able-bodied controls
Age, gender and body mass index matched control group of participants recruited among able-bodied personnel from Centro de Reabilitação do Norte, Unidade Local de Saúde de Gaia / Espinho, E.P.E. or their relatives, without any known CNS disease
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Injury occurred less than 6 months ago (subacute phase).
* Any neurological level of injury (AIS A-D).
Exclusion Criteria
* Major gastrointestinal surgery in the last 5 years.
* Active gastrointestinal diseases or other CNS diseases.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centro de Reabilitacao do Norte
OTHER
Unidade Local de Saude de Gaia e Espinho EPE
OTHER
Aveiro Institute of Biomedicine (iBiMED)
UNKNOWN
Aveiro University
OTHER
Centro Academico Clínico Egas Moniz Health Alliance
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Maria Ribeiro da Cunha, PhD
Role: PRINCIPAL_INVESTIGATOR
Centro de Reabilitação do Norte (CRN) / Unidade Local de Saúde Gaia e Espinho (ULSGE))
Sandra Vieira
Role: STUDY_DIRECTOR
Institute of Biomedicine - Aveiro University (iBiMED-UA)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centro de Reabilitação do Norte (CRN) / Unidade Local de Saúde Gaia e Espinho (ULSGE)
Vila Nova de Gaia, Porto District, Portugal
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
246/2019-2
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.